Quantcast

Latest Auxilium Pharmaceuticals Inc. Stories

2014-09-22 12:27:59

DUBLIN, Sept. 22, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) today commented on Auxilium Pharmaceuticals, Inc.'s (NASDAQ: AUXL) decision not to accept its proposal to acquire Auxilium for a per share consideration of $28.10 in a cash and stock transaction valued at $2.2 billion. The Company issued the following statement: We continue to believe that our transaction for Auxilium is compelling. We are providing a substantial premium and immediate cash value for...

2014-09-22 08:27:53

Board Unanimously Reaffirms Recommendation of QLT Transaction CHESTERBROOK, Pa., Sept. 22, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that its Board of Directors (the "Board") has reviewed the unsolicited, non-binding and conditional proposal from Endo International plc ("Endo") and, after consulting with its independent financial and legal advisors, has unanimously determined it is not a superior...

2014-09-18 08:28:56

Data Support CCH could be Used to Treat Two Affected Joints Concurrently; Positive Results Presented from Additional Studies Evaluating CCH Retreatment for Recurrent Contracture CHESTERBROOK, Pa., Sept. 18, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced the first presentation of positive safety and efficacy data from the AUX-CC-867 MULTICORD (MULtiple Treatment Investigation of Collagenase Optimizing the Resolution of...

2014-09-18 08:28:33

MOUNTAIN VIEW, Calif. and CHESTERBROOK, Pa., Sept. 18, 2014 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA(®) (avanafil). STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity. STENDRA is a prescription...

2014-09-17 08:28:56

Adopts One Year Stockholder Rights Plan CHESTERBROOK, Pa., Sept. 17, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today confirmed that Auxilium has received an unsolicited, non-binding proposal from Endo International plc (NASDAQ: ENDP) to acquire all of the outstanding shares of Auxilium common stock at a price of $28.10 per share in cash and Endo stock, subject to due diligence, financing and other conditions. A copy of...

2014-09-09 16:26:49

- Expected to Reduce Annual Operating Expenses by At Least $75 Million - CHESTERBROOK, Pa., Sept. 9, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced steps it is taking to reduce its costs and more fully support the Company's goal to drive earnings growth and build shareholder value. These steps are being launched after a comprehensive assessment of Auxilium's broadened product portfolio and current cost structure and...

2014-08-28 08:27:24

Study Results of Concurrent CCH Injections to Treat Two Dupuytren's Contracture Cords with Delayed Finger Extension Selected for Best Paper Session; Data Support Safe and Effective Use of CCH for Treatment of Two Affected Joints Concurrently CHESTERBROOK, Pa., Aug. 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that data from trials evaluating the use of collagenase clostridium histolyticum (CCH) for treating two...

2014-08-27 08:27:00

CHESTERBROOK, Pa., Aug. 27, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Morgan Stanley Healthcare Conference to be held September 8-10, 2014 in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 10:55 a.m. ET on Wednesday,...

2014-08-21 20:22:34

LYNBROOK, N.Y., Aug. 21, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced positive, statistically significant results from a randomized, double-blind Phase 2a study of CCH for the potential treatment of cellulite, or edematous fibrosclerotic panniculopathy. The results...

2014-08-21 08:28:27

Mid and High Level Doses Demonstrate Statistically Significant Improvement in Cellulite Across All Endpoints; Nearly 70% of Mid and High Dose Patients Satisfied or Very Satisfied with Results CHESTERBROOK, Pa., Aug. 21, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related